Nov 2017: diagnosed with Stage IV, High-Risk Neuroblastoma; Nov 2017-April 2019: completed standard treatment protocol / no evidence of disease (NED); April 2019-April 2021: enrolled in/completed DFMO clinical trial; April 2022: RELAPSE; April 2022-June 2023: completed relapse treatment protocol / NED (again); June 2023-June 2024: enrolled in “compassionate use” high-dose DFMO clinical trial; June 2024: RELAPSE #2; July 2025 NED (again)
Friday, October 16, 2020
Wednesday, June 17, 2020
Sunday, April 12, 2020
Friday, March 13, 2020
Sunday, February 23, 2020
Sunday, November 24, 2019
Friday, October 4, 2019
Thursday, September 12, 2019